SCHEMBL6900583

SCHEMBL6900583

CCOC(=O)C(C)Cc1ccc(Cl)c(N)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.43
TSHR P16473 1/20 0.43
CYP4F2 P78329 1/20 0.43
CYP4A11 Q02928 1/20 0.43
HPGD P15428 3/20 0.43
KDM4E B2RXH2 2/20 0.43
MAPK1 P28482 1/20 0.43
PNMT P11086 1/20 0.41
LMNA P02545 1/20 0.41
EPHX2 P34913 2/20 0.40
PPARG P37231 1/20 0.40
JAK2 O60674 1/20 0.39
JAK3 P52333 1/20 0.39
ALDH1A1 P00352 2/20 0.39
NPC1 O15118 1/20 0.39
CASP3 P42574 1/20 0.39
RAB9A P51151 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1903863 1.00 SMN1; SMN2 (0.43) SMN1; SMN2TSHRCYP4F2CYP4A11HPGD
SCHEMBL1907908 1.00 SMN1; SMN2 (0.43) SMN1; SMN2TSHRCYP4F2CYP4A11HPGD
SCHEMBL18455288 0.86 PNMT (0.40) SMN1; SMN2TSHRCYP4F2CYP4A11HPGD
SCHEMBL6901178 0.84 EPHX2 (0.54) SMN1; SMN2TSHRCYP4F2CYP4A11HPGD
SCHEMBL1906000 0.84 EPHX2 (0.54) SMN1; SMN2TSHRCYP4F2CYP4A11HPGD
SCHEMBL1930974 0.84 EPHX2 (0.41) SMN1; SMN2CYP4F2CYP4A11HPGDKDM4E
SCHEMBL6901708 0.84 EPHX2 (0.41) SMN1; SMN2CYP4F2CYP4A11HPGDKDM4E
SCHEMBL1931788 0.84 EPHX2 (0.41) SMN1; SMN2CYP4F2CYP4A11HPGDKDM4E
SCHEMBL1903633 0.84 EPHX2 (0.54) SMN1; SMN2TSHRCYP4F2CYP4A11HPGD
SCHEMBL15709525 0.83 KDM4E (0.49) SMN1; SMN2HPGDKDM4EMAPK1PNMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2852573-B1 N-[3-(2-CARBOXYETHYL)PHENYL]-PIPERIDIN-1-YL ACETAMIDE DERIVATIVES AND THEIR USE AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE Bayer Pharma AG (DE) 2017-02-01 EP disclosed
US-9309198-B2 N-[3-(2-carboxyethyl)phenyl]piperidin-1-ylacetamide derivatives and use thereof as activators of soluble guanylate cyclase BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-04-12 US disclosed
US-9309198-B2 N-[3-(2-carboxyethyl)phenyl]piperidin-1-ylacetamide derivatives and use thereof as activators of soluble guanylate cyclase BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-04-12 US disclosed
US-20150152050-A1 N-[3-(2-CARBOXYETHYL)PHENYL]PIPERIDIN-1-YLACETAMIDE DERIVATIVES AND USE THEREOF AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-06-04 US disclosed
US-20150152050-A1 N-[3-(2-CARBOXYETHYL)PHENYL]PIPERIDIN-1-YLACETAMIDE DERIVATIVES AND USE THEREOF AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-06-04 US disclosed
US-9018414-B2 Substituted 3-phenylpropionic acids and the use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-04-28 US disclosed
US-9018414-B2 Substituted 3-phenylpropionic acids and the use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-04-28 US disclosed
CN-104470895-A N-[3-(2-carboxyethyl)phenyl]piperidin-1-ylacetamide derivatives and use thereof as activators of soluble guanylate cyclase Bayer Pharma AG 2015-03-25 CN disclosed
US-20140142069-A1 SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-05-22 US disclosed
US-20140142069-A1 SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-05-22 US disclosed
US-20110130445-A1 SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-06-02 US disclosed
US-20110130445-A1 SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-06-02 US disclosed
WO-2011051165-A1 SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152050-A1 N-[3-(2-CARBOXYETHYL)PHENYL]PIPERIDIN-1-YLACETAMIDE DERIVATIVES AND USE THEREOF AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE GUCY1A2, GUCY1A1, GUCY1B2 SMN1; SMN2 2261/4885TSHR 3063/4885CYP4F2 3531/4885
US-20140142069-A1 SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF FABP3, PC, PAH SMN1; SMN2 3173/4885TSHR 3882/4885CYP4F2 748/4885
US-20110130445-A1 SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF FABP3, PC, PAH SMN1; SMN2 3173/4885TSHR 3882/4885CYP4F2 748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.